कंपनी का अवलोकन
Spectral AI, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry by leveraging artificial intelligence for predictive medical diagnostics in the United States. The company's core offering, the DeepView System, utilizes proprietary AI algorithms to analyze human tissue characteristics, effectively distinguishing between fully damaged, partially damaged, and healthy states to assist in clinical decision-making. This specialized technology positions the firm as a niche player aiming to enhance diagnostic accuracy through advanced computational methods rather than traditional imaging analysis. In terms of scale, the company maintains a market capitalization of $53.15M and employs 65 individuals to support its operations and product development. Despite the relatively small market cap and limited workforce, the annual revenue of $19.65M indicates that the business has achieved a level of commercial traction sufficient to sustain operations, though the figures suggest a smaller enterprise profile compared to large-cap medical device giants. The revenue figure relative to the market cap suggests a high valuation multiple, while the employee count reflects a lean organizational structure typical of technology-driven firms in the medical device space.
वित्तीय स्वास्थ्य
The financial statements reveal a company generating $19.65M in revenue over the trailing twelve months while reporting a net income loss of $-7,571,000 and an EBITDA of $-8,532,000. The substantial gap between the positive revenue of $19.65M and the significant negative net income highlights a heavy cost structure where operating expenses and other charges exceed earnings before interest, taxes, depreciation, and amortization. Specifically, the EBITDA figure of $-8,532,000 indicates that core business operations are currently burning cash, a common scenario for growth-stage medical technology firms but a critical factor for investors monitoring cash burn rates. The company holds $15.39M in cash reserves against $10.09M in total debt, providing a net cash position that offers some buffer against ongoing operational deficits. However, the debt-to-equity ratio is listed as N/A, and the negative P/E and Price to Book ratios further reflect the unprofitable nature of the equity base. The current ratio stands at 0.94, which indicates that the company's short-term liquid assets are insufficient to cover its immediate liabilities without relying on external financing or asset liquidation. Return on Equity is N/A due to the negative equity position, while the Return on Assets metric shows a negative figure of -32.1%, revealing that the company's assets are currently generating value that is less than the cost of capital or resulting in a net loss relative to the asset base.
मूल्यांकन आकलन
Valuation metrics for Spectral AI, Inc. present a complex picture given the lack of profitability, with a Trailing Twelve Months P/E Ratio of N/A and a Forward P/E of -1.94. The negative forward P/E implies that the market is pricing in future losses rather than current earnings power, suggesting an expectation of continued unprofitability or a reliance on non-operating income to turn the metric positive. The Price to Book ratio is recorded at -8.93, indicating that the stock trades at a significant discount relative to its book value, which is often a signal of distress or deep value for turnaround situations rather than a premium. Additionally, the Price to Sales ratio stands at 2.70, while the EV/EBITDA multiple is -5.61, suggesting that traditional earnings-based valuation models are not applicable and that investors are relying heavily on revenue and asset-based metrics. The stock's price has fluctuated within a 52-week range bounded by a high of $3.21 and a low of $1.12, and without a specific current price provided in the facts, the trading position relative to this range cannot be precisely calculated but the range defines the volatility envelope. The Beta value is 0.91, indicating that the stock's price volatility moves in tandem with the broader market, exhibiting slightly lower sensitivity to market swings than a beta of 1.0 would suggest.
Growth & Income
Growth dynamics for the company show a Revenue Growth (YoY) of -46.3%, while Earnings Growth (YoY) is N/A due to the lack of positive earnings in the prior period. The negative revenue growth indicates a contraction in sales over the last year, which is a significant concern for a medical device company that typically relies on steady adoption rates for its products. Since the earnings growth metric is not applicable, one cannot compare earnings expansion to revenue trends, but the decline in revenue suggests that the cost base is not being covered efficiently, exacerbating the negative net income. The company does not pay dividends, as evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning all available cash is retained for operations and R&D rather than distributed to shareholders. Consequently, the company reinvests its earnings—or rather, its cash reserves—into growth initiatives, though the current revenue decline challenges the sustainability of this strategy. The overall growth and income profile is characterized by revenue contraction and a complete absence of dividend income, relying entirely on the deep cash balance to fund future expansion and operational stability.